Gridai Technologies Corp (GRDX)

Nov 28, 2025, 8:00 AM EST - 6 days ago

Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"

Nov 19, 2025, 8:45 AM EST - 15 days ago

ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer

Nov 13, 2025, 8:35 AM EST - 21 days ago

Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy

Nov 6, 2025, 8:45 AM EST - 4 weeks ago

Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid

Oct 30, 2025, 9:00 AM EDT - 5 weeks ago

Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)

Oct 30, 2025, 6:00 AM EDT - 5 weeks ago

Entero Regains Nasdaq Compliance With Grid AI Acquisition

Oct 16, 2025, 8:40 AM EDT - 7 weeks ago

Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid

Oct 14, 2025, 11:00 AM EDT - 7 weeks ago

From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO)

Oct 14, 2025, 8:00 AM EDT - 7 weeks ago

Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It

Oct 2, 2025, 5:50 AM EDT - 2 months ago

Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus

FRMI

Oct 1, 2025, 4:05 PM EDT - 2 months ago

ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI

Oct 1, 2025, 8:30 AM EDT - 2 months ago

ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand

Aug 14, 2025, 9:15 AM EDT - 4 months ago

Entero Therapeutics, Inc. Announces Reverse Stock Split

Aug 11, 2025, 7:30 AM EDT - 4 months ago

Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules

Jun 13, 2025, 10:46 AM EDT - 6 months ago

FluroTech Ltd. Announces Change in Directors

MMA

Mar 24, 2025, 10:51 PM EDT - 9 months ago

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Feb 14, 2025, 4:00 PM EST - 10 months ago

Entero Therapeutics Appoints Richard Paolone as CEO

Feb 7, 2025, 3:22 PM EST - 10 months ago

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

PULM

Nov 14, 2024, 6:50 PM EST - 1 year ago

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

Nov 13, 2024, 7:00 AM EST - 1 year ago

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS ONCO VRNA

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

May 22, 2024, 7:00 AM EDT - 1 year ago

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

May 20, 2024, 7:00 AM EDT - 1 year ago

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference